I think one of our challenges is, so when we define symptomatic melanoma brain metastases, there’s not really a clear consensus definition on what that is, right? For this trial, we defined it as, you know, neurologic symptoms from the brain metastases and or requiring corticosteroids up to 8 milligrams of dexamethasone. Other clinical trials in symptomatic melanoma brain metastases, which are very few, and small cohorts, typically 15, 20 patients, may have defined it in slightly different ways...
I think one of our challenges is, so when we define symptomatic melanoma brain metastases, there’s not really a clear consensus definition on what that is, right? For this trial, we defined it as, you know, neurologic symptoms from the brain metastases and or requiring corticosteroids up to 8 milligrams of dexamethasone. Other clinical trials in symptomatic melanoma brain metastases, which are very few, and small cohorts, typically 15, 20 patients, may have defined it in slightly different ways. So I think to try to advance the research in melanoma brain metastases, and especially those with symptomatic disease who still have poor outcomes, I think we need to come to more of a consensus on how we’re defining these patients, and importantly, to actually conduct trials, right? Because most of the time, patients with symptomatic metastases are automatically excluded from a very large majority of melanoma clinical trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
